目的 了解2014—2018年北京、上海、廣州、成都、天津、鄭州、杭州七城市口服抗凝藥在房顫疾病中的應(yīng)用情況。方法 通過(guò)醫(yī)院處方合作分析項(xiàng)目，篩選出七城市共80家醫(yī)院診斷房顫的處方數(shù)據(jù)作為研究對(duì)象。對(duì)房顫患者就診人數(shù)、各藥物年度處方張數(shù)、金額、用藥頻度（DDDs）、限定日費(fèi)用（DDC）、排序比（B/A）等進(jìn)行統(tǒng)計(jì)，并比較口服抗凝藥物的使用現(xiàn)狀和趨勢(shì)。結(jié)果 2014—2018年，七城市房顫患者就診人數(shù)逐年增加，以2018年增加人數(shù)為著，較2017年房顫患者人數(shù)增加約127%。華法林的處方數(shù)量、處方金額、DDDs呈增長(zhǎng)態(tài)勢(shì)，但增長(zhǎng)緩慢，處方數(shù)量構(gòu)成比在逐年降低，由97%降至32%；處方金額構(gòu)成比由36%降至2%；DDDs構(gòu)成比由98%降至46%，增長(zhǎng)率由17%降至5%。利伐沙班和達(dá)比加群酯的處方數(shù)量、處方金額、DDDs都呈現(xiàn)較快的增長(zhǎng)趨勢(shì)。結(jié)論 無(wú)論是處方數(shù)量、處方金額、DDDs等新型口服抗凝藥的使用比例均逐漸超過(guò)了傳統(tǒng)抗凝藥華法林，房顫患者中臨床醫(yī)生使用新型抗凝藥的傾向性日益增高。但華法林作為一傳統(tǒng)經(jīng)典經(jīng)濟(jì)的抗凝藥物，新型口服抗凝藥并不能完全取代。

Objective To realize the application status of oral anticoagulant drugs used in atrial fibrillation disease (AF) in 80 hospitals in 7 cities including Beijing, Shanghai, Guangzhou, Chengdu, Tianjin, Zhengzhou, and Hangzhou from 2014 to 2018. Methods The information of outpatient prescriptions and inpatient medical records which used oral anticoagulants were screened out through the hospital prescription ananlysis project. The prescriptions with AF related-diagnosis were alslo selected. The prescriptions of oral anticoagulant drugs used in AF was statistically analyzed by the number of visits for AF, prescription amount, drug amount, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A). Results From 2014 to 2018, the number of patients with AF in 7 cities increased year by year, and the number of patients with AF increased by about 127% in 2018. The number of prescriptions, amount of prescriptions and DDDs of warfarin increased, but the growth was slow. The proportion above mentioned decreased year by year, from 97% to 32%, from 36% to 2%, and from 98% to 46%. The prescription quantity and prescription amount and DDDs of rivaroxaban and dabigatran showed a rapid growth trend. Conclusion The proportion of new oral anticoagulants such as prescription quantity, prescription amount, and DDDs gradually exceeded that of the traditional anticoagulant warfarin, and the tendency of clinicians to use new anticoagulants in patients with AF increased day by day. However, warfarin, as a classical anticoagulant, cannot be completely replaced by the new oral anticoagulant.

R972